Ulinastatin API is a polypeptide protease inhibitor extracted from human urine. It is mainly used to inhibit the activity of various enzymes in the body, such as trypsin, elastase, and lipase. It has anti-inflammatory, anti-shock and organ protection effects. It is commonly used to treat diseases such as acute pancreatitis, severe infection (such as sepsis), multiple organ failure, and postoperative inflammatory response. Ulinastatin reduces tissue damage by inhibiting the release of inflammatory factors, reducing free radical damage, and improving microcirculation. It has good safety and low risk of adverse reactions. It is widely used in the fields of intensive care and surgery and is an important auxiliary drug for anti-inflammatory treatment.
Shaanxi Medibridge Biotech Co., Ltd. focuses on the supply of pharmaceutical raw materials and research-use compounds. We support customers with stable quality, clear specification communication, flexible packaging options, and document-related support for different project stages.
Protein Core, Kunitz Domains and Glycosylation Sites
Ulinastatin, also known as urinary trypsin inhibitor (UTI), is a proteoglycan whose protein core is commonly called bikunin. Classic sequence studies describe human urinary bikunin as a 143-amino-acid protein with a short N-terminal segment and two Kunitz-type protease inhibitor domains. In mature bikunin, Ser10 carries a chondroitin sulfate chain and Asn45 carries an N-linked glycan. Specify the sequence numbering convention when reporting these sites, since numbering based on the AMBP precursor differs from that of mature bikunin.
|
Structural component |
Attributes to characterize |
Suitable analytical approaches |
|
Protein core |
Sequence identity, terminal heterogeneity, and potential clipping |
LC–MS/MS peptide mapping and terminal peptide analysis |
|
Two Kunitz domains |
Disulfide connectivity and domain integrity |
Reduced and non-reduced peptide mapping, with disulfide bond assignment |
|
Ser10-linked chondroitin sulfate chain |
Chain-length distribution, disaccharide composition, and sulfation |
Intact-chain profiling and disaccharide analysis after enzymatic digestion |
|
Asn45-linked N-glycan |
Site occupancy and glycoform distribution |
Site-specific glycopeptide LC–MS and released N-glycan profiling |
Protease Inhibition Profile and Assay Conditions
Trypsin inhibition is the defining activity used to assign ulinastatin potency. Published studies also describe inhibitory activity against proteases such as chymotrypsin, kallikrein, plasmin, and elastase. The measured response depends on the enzyme source, substrate, and assay conditions. Compendial trypsin inhibition potency and inhibition measurements for other proteases should be reported with their respective assay details.
For inhibition profiling, establish a baseline activity for each enzyme and report the enzyme and substrate concentrations, pH, temperature, and preincubation conditions. IC50 is the inhibitor concentration that produces half-maximal inhibition under the specified assay conditions. Kᵢ is an inhibition constant estimated using a kinetic model.

Chondroitin Sulfate and the Structure–Activity Relationship

An original study compared intact urinary trypsin inhibitor with the protein remaining after removal of its chondroitin sulfate chain. Under the reported conditions, the attached chain enhanced the protease inhibitory activity of the protein core. This finding supports examining glycan attributes alongside protein integrity when investigating a change in API potency.
A paired study can compare intact and glycan-treated samples for protein recovery, core integrity, and inhibitory activity. Disaccharide analysis characterizes the building blocks and sulfation profile of the chain. Intact-chain profiling provides information on chain length and its distribution. Combining these measurements helps determine whether an activity difference accompanies changes in glycan composition, chain length, or the protein core.
Lot Comparability and Orthogonal Analysis
A published comparison of ulinastatin preparations used SDS–PAGE, size-exclusion chromatography (SEC), capillary electrophoresis (CE), and MALDI–TOF mass spectrometry. The study also analyzed enzymatically released chondroitin sulfate disaccharides and N-linked oligosaccharides. These methods capture different attributes, including apparent size, electrophoretic mobility, molecular mass, and glycan composition.
|
Comparison dimension |
Complementary measurements |
Main purpose |
|
Identity and integrity |
Peptide mapping and intact molecular mass profiling |
Verify the protein core and characterize the major molecular populations. |
|
Size and fragmentation |
SEC with electrophoresis or mass spectrometry |
Investigate high-molecular-weight species, fragments, and unusual migration. |
|
Charge and glycan composition |
CE or ion-exchange chromatography with glycan profiling |
Investigate changes in charge variants and their relationship to glycan composition. |
|
Protein content and function |
Protein quantification and trypsin inhibition potency |
Compare protein recovery and inhibitory activity per unit of protein. |
Powder Reconstitution and Stability
For API supplied as a dried powder, evaluate dry-state storage and post-reconstitution stability separately. For dry material, track appearance, water content, and recovery of protein and inhibitory activity after reconstitution. For reconstituted samples, record clarity, pH, protein concentration, SEC profile, and trypsin inhibition potency. Document the container, hold time, and freeze–thaw history so that results can be interpreted against the conditions tested for that lot.
If potency decreases, interpret protein recovery, specific activity, and the molecular size profile together. Lower protein recovery with largely unchanged activity per milligram of protein can indicate adsorption, precipitation, or filtration loss. Stable protein recovery with lower specific activity warrants investigation of structural changes or assay interference. If new species appear by SEC, electrophoresis, mass spectrometry, or glycan analysis can help characterize them.

FAQ
What is Ulinastatin used for?
Ulinastatin is a serine protease inhibitor used in clinical settings-primarily in select Asian and international markets such as Japan, China, South Korea, and India-to manage acute inflammatory and critical care conditions.
Who are the top 3 API manufacturers in the world?
The global active pharmaceutical ingredient (API) market features several prominent players known for massive production scale, custom synthesis, and contract development and manufacturing organization (CDMO) services.
What are the big 4 in pharma?
In the pharmaceutical and biopharmaceutical industry, the term "Big 4" doesn't refer to a single fixed group, as rankings shift depending on whether you measure by total revenue, pure prescription (Rx) drug sales, or market capitalization.
What is the largest pharma company in the world?
Eli Lilly and Company is the largest pharmaceutical company in the world by market capitalization, valued at over $1.29 trillion.
If you are looking for a high-quality Ulinastatin API manufacturer with whom you can establish a long-term, stable partnership, then Shaanxi Medibridge Biotech Co., Ltd. would be your best business partner. Don't hesitate to contact us at hi@medibridgeapi.com.
Hot Tags: ulinastatin api, China ulinastatin api manufacturers, suppliers, factory, cilostazol pharmaceutical research material, cilostazol research compound, omadacycline pharmaceutical synthesis material, rapamycin immunosuppressant ingredient, telmisartan laboratory grade powder, telmisartan therapeutic compound

